Update on calcium pyrophosphate deposition.

Area of Science:

• Rheumatology
• Crystal Arthropathies
• Osteoarthritis Research

Background:

• Calcium pyrophosphate crystal deposition (CPPD) is associated with aging, osteoarthritis (OA), metabolic diseases, and ANKH gene variations.
• CPPD often affects multiple joints and has specific associations with knee OA, but not hip OA.
• Emerging associations include knee malalignment, low bone density, and soft-tissue calcification.

Purpose of the Study:

• To review the associations, clinical presentations, diagnostic methods, and treatment strategies for Calcium Pyrophosphate Crystal Deposition (CPPD).
• To highlight the relationship between CPPD, osteoarthritis, and other musculoskeletal conditions.
• To discuss current and emerging therapeutic approaches for CPPD-related arthritis.

Main Methods:

• Literature review of studies on Calcium Pyrophosphate Crystal Deposition (CPPD).
• Analysis of associations between CPPD and osteoarthritis, genetic factors, and other conditions.
• Evaluation of diagnostic techniques and treatment options for CPPD and associated arthritis.

Main Results:

• CPPD is linked to aging, knee OA, knee malalignment, low bone density, and soft-tissue calcification.
• CPPD can manifest as asymptomatic crystal deposition, acute CPP crystal arthritis, or chronic inflammatory arthritis.
• Joint aspiration is the gold standard for diagnosis, though other methods are developing.

Conclusions:

• CPPD management is symptomatic, with treatments like colchicine and corticosteroids for acute or chronic arthritis.
• Screening for metabolic abnormalities is advised for specific CPPD cases, though often unrewarding.
• Unlike gout, no treatments currently eliminate CPP crystal deposits, and the efficacy of anti-IL1 agents requires further study.